Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study

  • Antonio Marchini*
  • , Laurent Daeffler
  • , Vitaly I. Pozdeev
  • , Assia Angelova
  • , Jean Rommelaere
  • *Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    77 Citations (Scopus)

    Abstract

    Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.

    Original languageEnglish
    Article number1848
    JournalFrontiers in Immunology
    Volume10
    Issue numberAUG
    DOIs
    Publication statusPublished - 2019

    Keywords

    • Checkpoint blockade
    • Combination therapy
    • H-1PV
    • Immunogenic cell death
    • Immunotherapy
    • Oncolytic viruses
    • Tumor microenvironment

    Fingerprint

    Dive into the research topics of 'Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study'. Together they form a unique fingerprint.

    Cite this